Reliance Global Group (EZRA) Proxy filing summary

Executive summary

• Completed a strategic investment in Innervate Radiopharmaceuticals, acquiring up to 421,053 units at $4.75 per unit for a total of $2,000,001.75, with $500,000 funded at closing and the remainder in staged installments.

• The investment targets late-stage PET imaging for neuroblastoma, with expansion potential in cardiovascular and neurodegenerative diseases, and possible Priority Review Voucher upside.

• LifeSci Global Group LLC, a newly formed subsidiary, holds 51% by the company and 49% by a management group including directors and executives.

• The transaction aligns with a broader strategy to build exposure to high-growth healthcare platforms through disciplined capital allocation.

Voting matters and shareholder proposals

• The investment and related transactions were reviewed and approved by independent and disinterested board members, with interested directors recusing themselves from deliberations and voting.

Board of directors and corporate governance

• Formation of LifeSci Global Group LLC involved related-party interests, with directors and executives holding indirect equity stakes.

• Board committee changes effective April 28, 2026: Mr. Korman removed from Audit, Compensation, and Nominating Committees; independent directors appointed to all committees.

• All board committees now consist solely of independent directors under Nasdaq and SEC rules.